Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Sequence of amyloid fibrils from renal AL amyloidosis

ABSTRACT: De novo sequencing of amyloid fibrils from renal AL amyloidosis based on LC-MS/MS

ORGANISM(S): Homo Sapiens

SUBMITTER: Kun Zhao

PROVIDER: PXD066587 | iProX | Fri Jul 25 00:00:00 GMT+01:00 2025

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

A mouse model of cardiac AL amyloidosis unveils mechanisms of tissue accumulation and toxicity of amyloid fibrils

Project description:Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis. The lack of reliable in vivo models hinders the study of the disease in its physiological context. We developped a transgenic mouse model producing high amounts of a human AL free light chain (LC). While mice exceptionnaly develop spontaneous AL amyloidosis and do not exhibit organ toxicity due to the circulating amyloidogenic LC, a single injection of amyloid fibrils, made up of the variable domain (VL) of the human LC, or soluble VL led to amyloid deposits, mainly in heart. The biochemical composition and the fragmentation pattern of the LC in the fibrils are highly similar to that of human AL fibrils, arguing for a conserved mechanism of amyloid fibrils formation. Amyloidosis positive mice also develop an early cardiac dysfunction, with increased NT-proBNP, diastolic dysfunction and remodeling of the extracellular matrix. Overall, this transgenic mice closely reproduces human cardiac AL amyloidosis and shows that a partial degradation of the LC initiate amyloid fibril formations in vivo. Accumulation of AL amyloid fibrils, rather than the soluble LC, drive the initial cardiac dysfunction. This model fills an important gap for research on AL amyloidosis and preclinical evaluation of new therapies.

2025-01-17 | GSE286368 | GEO

Protein identification in purified amyloid fibrils

Project description:We identified the protein in purified AL amyloid fibrils extracted from heart tissues from transgenic mice developing AL amyloidosis.

2025-01-17 | PXD059000 | Pride

Amyloids “at the border”: deep mutagenesis and random sequence extension reveal an incomplete amyloid-forming motif in Bri2 that turns amyloidogenic upon C-terminal extension

Project description:Stop-loss mutations cause over twenty different diseases. The effects of stop-loss mutations can have multiple consequences that are, however, hard to predict. Stop-loss in ITM2B/BRI2 results in C-terminal extension of the encoded protein and, upon furin cleavage, in the production of two 34 amino acid long peptides, ADan and ABri, that accumulate as amyloids in the brains of patients affected by familial Danish and British Dementia. To systematically explore the consequences of Bri2 C-terminal extension, here, we measure amyloid formation for 676 ADan substitutions and identify the region that forms the putative amyloid core of ADan fibrils, located between positions 20 and 26, where stop-loss occurs. Moreover, we measure amyloid formation for ~18,000 random C-terminal extensions of Bri2 and find that ~32% of these sequences can nucleate amyloids. We find that the amino acid composition of these nucleating sequences varies with peptide length and that short extensions of 2 specific amino acids (Aliphatics, Aromatics and Cysteines) are sufficient to generate novel amyloid cores. Overall, our results show that the C-terminus of Bri2 contains an incomplete amyloid motif that can turn amyloidogenic upon extension. C-terminal extension with de novo formation of amyloid motifs may thus be a widespread pathogenic mechanism resulting from stop-loss, highlighting the importance of determining the impact of these mutations for other sequences across the genome.

2024-08-02 | GSE270792 | GEO

A mouse model of cardiac AL amyloidosis unveils mechanisms of tissue accumulation and toxicity of amyloid fibrils

Project description:A mouse model of cardiac AL amyloidosis unveils mechanisms of tissue accumulation and toxicity of amyloid fibrils

2025-01-17 | PXD059046 | Pride

Light chain amyloid fibrils from an AL amyloidosis patient (case 1), abdominal fat biopsy

Project description:In this study, we successfully extracted and resolved the high-resolution structure of amyloid fibrils from biopsy sample obtained from a living AL patient using cryo-EM.

2025-12-23 | PXD065430 | Pride

Light chain amyloid fibrils from an AL amyloidosis patient (case 3), abdominal fat biopsy

Project description:In this study, we successfully extracted and resolved the high-resolution structure of amyloid fibrils from abdominal fat biopsy sample obtained from a living AL patient using cryo-EM.

2025-12-23 | PXD065432 | Pride

Light chain amyloid fibrils from an AL amyloidosis patient (case 2), abdominal fat biopsy

2025-12-23 | PXD065431 | Pride

Consistent Amyloid Fibril Structures Across Multiple Organs and Patients in ATTRv-T60A Amyloidosis Revealed by Cryo-EM

Project description:Cardiac ATTRv-T60A amyloid fibrils from three different patients, and ATTRv-T60A fibrils from thyroid, explanted kidney, and explanted liver from one of the patients (tissues obtained from autopsy and transplant surgery). Identification of tryptic and non-tryptic fragments in ATTRv-V30M). Cardiac ATTR fibrils (patient 1): Sample ID: 1176938 Cardiac ATTR fibrils (patient 2): Sample ID: 1176937 Cardiac ATTR fibrils from (patient 3): Sample ID: 1176932 Thyroid ATTR fibrils from (patient 3): Sample ID: 1176934 Renal ATTR fibrils from (patient 3): Sample ID: 1176933 Hepatic ATTR fibrils from (patient 3): Sample ID: 1176935

2024-08-22 | MSV000095675 | MassIVE

Uncovering Cell Type-Specific Phenotypes Using a Novel Human In vitro Model of Transthyretin Amyloid Cardiomyopathy

Project description:Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the misfolding of transthyretin (TTR), fibrillogenesis, and progressive amyloid fibril deposition in the myocardium, leading to cardiac dysfunction with dismal prognosis. In ATTR-CM, either destabilizing mutations (variant TTR, ATTRv) or ageing-associated processes (wild-type TTR, ATTRwt) lead to the formation of TTR amyloid fibrils. Due to a lack of representative disease models, ATTR-CM disease mechanisms are largely unknown, thereby limiting disease understanding and therapeutic discovery. Methods and Results: Here, we report a novel in vitro ATTR-CM model which uncovers cell type-specific disease phenotypes by exposing the three major human cardiac cell types to TTR fibrils, thereby providing novel insights into the cellular mechanisms of ATTR-CM disease. Human recombinant TTR proteins (WT, V122I, V30M) and respective fibrils were generated and characterized using Thioflavin T, Amytracker, Congo red and dot blot analyses. Seeding human induced pluripotent stem cell-derived-cardiomyocytes (hiPSC-CMs) and endothelial cells (ECs) on TTR fibrils resulted in reduced cell viability. Confocal microscopy revealed extracellular localization of TTR fibrils to hiPSC-CMs, leading to sarcomere disruption, altered calcium handling and disrupted electromechanical coupling, while ECs showed a reduced migration capacity with aberrant cell morphology. hiPSC-fibroblasts (hiPSC-FBs) were largely unaffected by TTR fibrils, presenting normal viability, but showing enhanced localization with TTR fibrils. Our model shows that WT and variant TTR fibrils lead to cell type-specific phenotypes, providing novel insights into the underlying cellular disease mechanisms of ATTR-CM, thereby facilitating the identification of novel therapeutic targets and biomarkers.

2025-06-11 | GSE294021 | GEO

Helical superstructures between amyloid and collagen VI in heart derived fibrils from a patient with Light Chain Amyloidosis

Project description:we investigated the N-glycosylation of the amyloid fibrils extracted from the heart of a patient affected by AL amyloidosis, using a proteomic approach to evaluate indirectly the presence of glycans in immunoglobulin light chains.

2024-07-02 | PXD049369 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data